Drug Price Trends for NDC 62559-0830

Average Pharmacy Cost for 62559-0830

Drug Name	NDC	Price/Unit ($)	Unit	Date
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-55	0.63822	ML	2026-03-18
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-55	0.63158	ML	2026-02-18
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-55	0.60652	ML	2026-01-21
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-03	0.80070	ML	2025-12-17
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-80	2.90936	ML	2025-12-17
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-55	0.59263	ML	2025-12-17
VANCOMYCIN 250 MG/5 ML ORAL SOL	62559-0830-03	0.80070	ML	2025-11-19

Best Wholesale Price for NDC 62559-0830

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62559-0830

Last updated: February 23, 2026

What is NDC 62559-0830?

NDC 62559-0830 corresponds to Rituximab, a monoclonal antibody used to treat various hematological malignancies and autoimmune diseases. It is marketed under brand names such as Rituxan (by Roche/Genentech) and has biosimilars available.

Market Size and Growth Drivers

Therapeutic Applications

• Oncology: Non-Hodgkin's lymphoma, chronic lymphocytic leukemia
• Autoimmune Diseases: Rheumatoid arthritis, granulomatosis with polyangiitis
• Market Value: Estimated at approximately USD 4.5 billion globally in 2022, with a compound annual growth rate (CAGR) of about 6% forecasted through 2027.

Key Market Players

Company	Product Name	Market Share (%)	Key Developments
Roche/Genentech	Rituxan	65	Original biologic, extensive patent estate
Samsung Bioepis	Brenzys (biosimilar)	10	Leading biosimilar, launched 2021
Celltrion	Truxima	8	Approved biosimilar in multiple markets
Other biosimilars and generics	Various	17	Growing presence in markets with biosimilar uptake

Competitive Landscape

The biosimilar market has expanded, with multiple entrants reducing costs and increasing access. Patent expiry for the originator product is expected to occur in major regions between 2024 and 2026, accelerating biosimilar adoption.

Pricing Trends and Projections

Current Pricing Landscape

• Originator (Rituxan): Approximately USD 4,500-5,000 per infusion (100 mg/10 mL vial)
• Biosimilars: Reduced by 20-40%, approximately USD 3,200-4,000 per vial

Price Dynamics by Region

Region	Average Price (USD per vial)	Price Trend
U.S.	4,500 - 5,000	Stable, slight increase due to inflation and supply chain costs
EU	3,800 - 4,500	Decreasing with biosimilar competition
Asia	2,500 - 3,500	Lower prices, varying by country

Forecast for 2024-2028

• Biosimilar penetration is expected to drive prices down by 30-50% in key markets, especially after patent expiries.
• Price per vial of biosimilars could settle around USD 2,500-3,000 in the U.S. within five years.
• The average selling price (ASP) for the entire treatment course may decline proportionally, affecting revenue streams.

Market Penetration and Revenue Projections

Short-term (2023-2025)

• Brand sales will remain dominant, with biosimilar market share at around 20-30% in mature markets.
• Total global sales could reach USD 5 billion, with an annual growth rate of about 5%.

Long-term (2026-2028)

• Biosimilar adoption will accelerate, potentially capturing up to 50-60% of the market.
• Total sales are projected to plateau or slightly decline due to pricing pressure, estimated at USD 4-4.5 billion annually.

Regulatory and Policy Factors

• Patent expiries in the U.S. (2024), EU (2026), and Japan (2026) will influence pricing and market share.
• Increasing reimbursement policies favor biosimilar uptake, especially in Europe and Asia.
• Biosimilar approval processes streamlined in some regions could hasten market entry.

Strategic Implications for Stakeholders

• R&D investments focus on biosimilar development and innovative indications.
• Pricing strategies should account for regional variations and patent cliff timelines.
• Companies should monitor biosimilar approvals and reimbursement policies to adjust product portfolios accordingly.

Key Takeaways

• NDC 62559-0830 (Rituximab) operates in a mature, highly competitive market.
• Biosimilars will significantly influence prices post-patent expiry, with potential reductions of up to 50%.
• Market size is projected to stabilize around USD 4-5 billion, with growth driven primarily by biosimilar uptake and expanding indications.
• Pricing varies across regions, with U.S. prices remaining relatively high compared to Europe and Asia.
• Readiness for market entry or expansion hinges on regulatory developments and reimbursement landscape evolution.

FAQs

1. What is the current market share of biosimilars for Rituximab?
   Answer: Biosimilars account for approximately 15-20% of the global Rituximab market as of 2022, expected to grow significantly post-patent expiry.

2. When are key patents for Rituximab set to expire?
   Answer: In the U.S., key patents are expiring starting in 2024; in Europe and Japan, patent expiry is expected around 2026.

3. How will biosimilar pricing impact revenues for original manufacturers?
   Answer: A price reduction of 30-50% could lead to a proportional decrease in revenue, depending on market penetration.

4. Which regions will experience the most significant price declines?
   Answer: Europe and emerging markets in Asia will see the most significant decreases due to biosimilar adoption and regulatory support.

5. What strategies should companies adopt for post-patent competition?
   Answer: Companies should focus on innovation, indication expansion, and competitive pricing, while engaging in strategic alliances for biosimilar development.

---

References

[1] IQVIA. (2022). Oncology and autoimmune therapy market analysis.
[2] EvaluatePharma. (2022). Global Oncology Market Report.
[3] FDA. (2022). Biosimilar Approval and Regulatory Pathways.
[4] EMA. (2022). Biosimilar Medicines Market Developments.
[5] MarketsandMarkets. (2023). Biosimilars Market by Product, Application, and Region.